ribavirin has been researched along with amg531 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Godeau, B | 1 |
| McHutchison, JG; Patel, K; Tillmann, HL | 1 |
| Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY | 1 |
| Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P | 1 |
2 trial(s) available for ribavirin and amg531
| Article | Year |
|---|---|
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2015 |
3 other study(ies) available for ribavirin and amg531
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors | 2009 |
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2009 |